fashion -WSS

fashion

author：entertainment 2025-08-06 04:47:33 - browse：39122

Drew Weissman (left) and Katalin Karikó (right) — Drew Weissman (left) and Katalin Karikó, whose longtime partnership was recognized with a Nobel Prize on Monday. Peggy Peterson/Penn Medicine

The most noteworthy aspect of awarding the Nobel Prize in medicine or physiology to two pioneers of mRNA research was not who won Monday — Katalin Karikó and Drew Weissman were widely expected to get the accolade for discoveries that made it possible to deliver the finicky molecule to cells and enabled the record-breaking development of vaccines that tamed the Covid-19 pandemic. It was the way the two scientists worked together.

The Nobel committee framed Karikó and Weissman’s work as a prime example of complementary expertise, with Karikó focused on RNA-based therapies and Weissman bringing a deep knowledge about immune responses to vaccines. In a rare moment for science’s top honor, which elevates the individual contributions of one, two, or at most, three researchers to a particularly impactful breakthrough, it is a celebration of a true scientific partnership — a durable and fruitful collaboration spanning more than two decades of working shoulder-to-shoulder at the lab bench that turned a scientific backwater into a blockbuster technology.

“We couldn’t get funding, we couldn’t get publications, we couldn’t get people to notice mRNA as something interesting,” Weissman told reporters at a press conference Monday at the University of Pennsylvania. “But Kati lit the match and we spent the rest of the next 20 plus years working together figuring out how to get it to work. We would sit together in 1997 and afterwards and talk about all the things we thought RNA could do. And that’s why we never gave up,” he said.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： Scientific mystery highlights the blind spots in genomics databases

leisure time

WSS

Insurer loopholes limit power of law against surprise medical bills

Scientists uncover potential path to treating deadly childhood tumor

Robert F. Kennedy is pitching centrism on health, even on abortion

UnitedHealth, in a surprise, takes aim at Steward’s physician group

To avoid data mishandling cases, universities eye AI and other tools

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

knowledge

fashion

entertainment

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Republican states more likely to report Covid vaccine side effects

Jerome Adams on the need for new antivirals for Covid

Four alarming medical procedures we’re glad history forgot

Anesthesiologist group: stop taking Ozempic before surgery

Medicare threatens to cut off funding for HCA's Mission hospital

The high cost of giving birth even with insurance

How digital tools helped lower hypertension in marginalized patients

The cancer drug shortage isn’t new — and neither are the solutions

What should King Charles tell the public about his cancer?

hotspot

A disappointing year of Humira biosimilars

The dental labor crisis is a moment of opportunity

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

Readout LOUD podcast: How biotech is using artificial intelligence

Alzheimer's risk factor APOE4 may be a distinct form of the disease

focus

leisure time

hotspot

entertainment